Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 580

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 580
---
 | ) |     | $    | (11,445 | ) |     | $      | (3,179 | ) |

375

Revenues Licensing revenues were zero for the three and nine months ended September 30, 2024. Licensing revenues were zero for the three months ended September 30, 2023 and $5.0 million for the nine months ended September 30, 2023. The licensing revenues in 2023 were due to the achievement of a development milestone pursuant to the Merck Neuromuscular License Agreement. Collaboration revenues were zero for the three and nine months ended September 30, 2024. Collaboration revenues were zero for the three months ended September 30, 2023 and $442,000 for the nine months ended September 30, 2023 as a result of research services provided in 2023 under the Merck Neuromuscular License Agreement pursuant to which Kineta became a successor in interest in connection with the Merger. Upon completion of the Merger, Kineta had $442,000 in deferred revenue under the Merck Neuromuscular License Agreement. As of December 31, 2023, Kineta has completed the project services and had zero in deferred revenue under the Merck Neuromuscular License Agreement. Kineta does not expect to earn any revenue from this license in 2024. Research and Development Expenses The following table summarizes Kineta’s research and development expenses by program and category for the periods presented:

| Direct external program expenses:       |     | Three Months Ended 
 September 30,      
 2024               
 (in thousands)     |     |     | 2023 |       |   |     | Change |        |   |     | Nine Months Ended 
 September 30,     
 2024              
 (in thousands)    |       |     | 2023 |       |     | Change |        |   |
|:----------------------------------------|:----|:-------------------|----:|:----|:-----|------:|:--|:----|:-------|-------:|:--|:----|:------------------|------:|:----|:-----|------:|:----|:-------|-------:|:--|
| KVA12123 program                        |     | $                  | 676 |     | $    | 1,301 |   |     | $      |   (625 | ) |     | $                 | 3,230